Laboratoire Dazont has been acquired by SBM Company
The shareholders of Laboratoire Dazont have sold the company to SBM Company.
Created in 2008, Laboratoire Dazont is a France-based company specialized in the design, manufacture and distribution of natural veterinary solutions for pharmacies and parapharmacies. The company offers a complete range of approximately 50 references of natural products, including aromatherapy, petcare, and products and food supplements for dogs and cats under the Vetoform and Vetonut brands. Laboratoire Dazont offers its solutions to 750 pharmacies and parapharmacies in France, including key accounts such as E. Leclerc and Santédiscount.
Created in 1994, SBM Company is a family-owned French group with presence in more than 31 countries throughout Europe and North America. SBM designs, homologates, produces and markets products for the care and protection of crops, gardens and homes. In 2021, the group generated approximately US$360 million in sales, 60% internationally.
Oaklins’ team in France acted as M&A advisor to Laboratoire Dazont in the disposal of the company to SBM Company.
Contáctese con el equipo de la transacción
Transacciones relacionadas
Leika Medical Equipments Ltd. has been acquired by Angus Capital
The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.
Aprenda másPhen’X Technologies has sold a majority stake to Ciclad
The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.
Aprenda másMedis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments
Medis Medical Imaging Systems B.V., a leading cardiac imaging software company, have completed a strategic investment to further develop its revolutionary non-invasive cardiovascular imaging solution. The company has announced its collaboration with GE HealthCare (Nasdaq: GEHC), a global leader in medical technology, pharmaceutical diagnostics and innovation in digital solutions, to contribute to the advancement of precision care in the diagnosis and treatment of coronary artery disease (CAD).
Aprenda más